Patents Assigned to ONK Therapeutics Limited
  • DOUBLE KNOCKOUT NATURAL KILLER CELLS
    Publication number: 20240307443
    Abstract: NK cells and NK cell lines are modified to increase their cytotoxicity. proliferation. metabolic profile and persistence. wherein the cells and compositions thereof have a use in the treatment of cancer.
    Type: Application
    Filed: June 20, 2022
    Publication date: September 19, 2024
    Applicant: ONK THERAPEUTICS LIMITED
    Inventor: Michael Eamonn Peter O'DWYER
  • Modified natural killer cells and natural killer cell lines having increased cytotoxicity
    Patent number: 10960064
    Abstract: NK cells and NK cell lines are modified to increase cytotoxicity, wherein the cells and compositions thereof have a use in the treatment of cancer. Production of modified NK cells and NK cell lines is via genetic modification to remove checkpoint inhibitory receptor expression and/or add mutant (variant) TRAIL ligand expression.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: March 30, 2021
    Assignee: ONK THERAPEUTICS LIMITED
    Inventor: Michael O'Dwyer
  • Modified natural killer cells and natural killer cell lines having increased cytotoxicity
    Patent number: 10906951
    Abstract: NK cells and NK cell lines are modified to increase cytotoxicity, wherein the cells and compositions thereof have a use in the treatment of cancer. Production of modified NK cells and NK cell lines is via genetic modification to add mutant (variant) TRAIL ligand expression.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: February 2, 2021
    Assignee: ONK THERAPEUTICS LIMITED
    Inventor: Michael Eamon Peter O'Dwyer
  • Method of treating multiple myeloma using natural killer cells expressing a chimeric antigen receptor for CD38
    Patent number: 10799536
    Abstract: Disclosed herein are engineered natural killer cells that have been modified to express chimeric antigen receptors (CARs). The cells optionally contain other modifications that improve tumor specific cytotoxicity and homing to tumor sites. Also contemplated are methods for using the engineered natural killer cells to treat patients with cancer.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: October 13, 2020
    Assignee: ONK Therapeutics Limited
    Inventor: Michael Eamon Peter O'Dwyer